Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

5 Can’t-Miss Health-Care Events This Week: Exelixis, Inc. (EXEL), Regeneron Pharmaceuticals Inc (REGN)

Page 1 of 2

With no major health-care conferences on the docket this week, and the Food and Drug Administration ruling two days early on Celgene Corporation (NASDAQ:CELG)‘s multiple myeloma drug, Pomalyst, this week’s main focus is earnings, earnings, and more earnings. Just as we did last week, we have five big names reporting, and you’d be small-“f” foolish to miss out on any of them.

The week starts off with an important report from my personal No. 1 biotech to watch in 2013Exelixis, Inc. (NASDAQ:EXEL). The fourth-quarter report, expected Monday, shouldn’t include any major surprises. What I’ll be looking for, however, is the company’s updated 2013 sales forecast now that Cometriq, its metastatic medullary thyroid cancer drug, is available in the United States. I’d keep your eye on Exelixis’ cash balance, but I don’t anticipate that it will dip all too much. Cometriq’s sales forecast could be the factor that causes this company to move up or down in a big way.

Exelixis, Inc. (NASDAQ:EXEL)On Tuesday, we’ll hear from Seattle Genetics, Inc. (NASDAQ:SGEN), developer of antibody-drug conjugates that deliver chemotherapy toxins directly to tumors. Investors will definitely be looking for an improvement in sales from Adcetris, the company’s only FDA-approved drug designed to be a second-line treatment of Hodgkin’s lymphoma. I will be ignoring most of the Adcetris data and focusing on what upcoming data Seattle Genetics has in store. With its $3.6 billion market value, what I can say for certain is that its loss had better not be much higher (if at all) from the $0.11 per share currently forecast.

Health-benefit solutions provider WellCare Health Plans, Inc. (NYSE:WCG) steps up to the plate on Wednesday and should offer an interesting report from a value investors’ perspective, as it’s been the laggard of the group. The Affordable Care Act is expected to cap insurers’ earnings and disallow them from turning away patients with pre-existing conditions, but it also will bring millions of newly insured Americans into the fold. I suspect thast WellCare’s guidance will be in-line with, if not higher than, what’s currently projected on Wall Street as investors underestimate the cost-cutting ability of the health-benefits sector.

Finally, Thursday will bring the two most important reports of the week from the biotech sector: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!